186 related articles for article (PubMed ID: 20489208)
41. Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin.
Leontieva OV; Demidenko ZN; Gudkov AV; Blagosklonny MV
PLoS One; 2011; 6(10):e26126. PubMed ID: 22022534
[TBL] [Abstract][Full Text] [Related]
42. Weak p53 permits senescence during cell cycle arrest.
Leontieva OV; Gudkov AV; Blagosklonny MV
Cell Cycle; 2010 Nov; 9(21):4323-7. PubMed ID: 21051933
[TBL] [Abstract][Full Text] [Related]
43. Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation.
Pan D; Pan LZ; Hill R; Marcato P; Shmulevitz M; Vassilev LT; Lee PW
Br J Cancer; 2011 Sep; 105(7):1012-22. PubMed ID: 21863032
[TBL] [Abstract][Full Text] [Related]
44. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis.
Davaadelger B; Perez RE; Zhou Y; Duan L; Gitelis S; Maki CG
Cancer Biol Ther; 2017 Nov; 18(11):895-903. PubMed ID: 28696156
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
46. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
Kojima K; Konopleva M; Samudio IJ; Ruvolo V; Andreeff M
Cancer Res; 2007 Apr; 67(7):3210-9. PubMed ID: 17409429
[TBL] [Abstract][Full Text] [Related]
47. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.
Cao C; Shinohara ET; Subhawong TK; Geng L; Kim KW; Albert JM; Hallahan DE; Lu B
Mol Cancer Ther; 2006 Feb; 5(2):411-7. PubMed ID: 16505116
[TBL] [Abstract][Full Text] [Related]
48. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
49. Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death.
Marcus JM; Burke RT; Doak AE; Park S; Orth JD
Cell Cycle; 2018; 17(11):1329-1344. PubMed ID: 30037299
[TBL] [Abstract][Full Text] [Related]
50. The hydrophobically-tagged MDM2-p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a.
Nietzold F; Rubner S; Berg T
Chem Commun (Camb); 2019 Nov; 55(95):14351-14354. PubMed ID: 31720601
[TBL] [Abstract][Full Text] [Related]
51. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
He T; Guo J; Song H; Zhu H; Di X; Min H; Wang Y; Chen G; Dai W; Ma J; Sun X; Ma J
Pathol Oncol Res; 2018 Jan; 24(1):75-81. PubMed ID: 28341911
[TBL] [Abstract][Full Text] [Related]
52. Nutlin-3a is a potential therapeutic for ewing sarcoma.
Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
[TBL] [Abstract][Full Text] [Related]
53. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
54. Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors.
Veneziani I; Infante P; Ferretti E; Melaiu O; Battistelli C; Lucarini V; Compagnone M; Nicoletti C; Castellano A; Petrini S; Ognibene M; Pezzolo A; Di Marcotullio L; Bei R; Moretta L; Pistoia V; Fruci D; Barnaba V; Locatelli F; Cifaldi L
Cancer Immunol Res; 2021 Feb; 9(2):170-183. PubMed ID: 33303573
[TBL] [Abstract][Full Text] [Related]
55. Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol.
Zajkowicz A; Krześniak M; Matuszczyk I; Głowala-Kosińska M; Butkiewicz D; Rusin M
Mol Biol Rep; 2013 Aug; 40(8):5013-26. PubMed ID: 23666059
[TBL] [Abstract][Full Text] [Related]
56. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
57. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
[TBL] [Abstract][Full Text] [Related]
58. Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3.
Huang B; Vassilev LT
Aging (Albany NY); 2009 Sep; 1(10):845-54. PubMed ID: 20157557
[TBL] [Abstract][Full Text] [Related]
59. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
60. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]